Selective left-lobe atrophy by nodularin treatment accompanied by reduced protein phosphatase 1/2A and increased peroxisome proliferation in rat liver

International Journal of Cancer

Volumn 91, Issue 1, 2001, Pages 32-40

  Lim, In Kyoung ^a   Park, Tae Jun ^a   Park, Sang Chul ^b   Yoon, Gyesoon ^a   Kwak, Choong Sil ^b   Lee, Myung Soog ^a   Song, Kye Yong ^c   Choi, Yang Kyu ^d   Hyun, Byung Hwa ^d  

^a Ajou University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Chung Ang University   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Left lobe atrophy; Nodularin; Peroxisome proliferation; Protein phosphatase 1 2A

Indexed keywords

CYTOCHROME P450; NODULARIN; PALMITOYL COENZYME A; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BCL X;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN ATROPHY; CAUDATE NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; LIVER CELL; MALE; NONHUMAN; PEROXISOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TEMPORAL LOBE;

ALKYLATING AGENTS; ANIMALS; APOPTOSIS; ATROPHY; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOGENS; DIETHYLNITROSAMINE; LIVER; LIVER NEOPLASMS; MALE; ORGAN SIZE; OXIDOREDUCTASES; PEPTIDES, CYCLIC; PEROXISOMES; PHOSPHOPROTEIN PHOSPHATASE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, INBRED F344; TIME FACTORS;

EID: 0035195299     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010101)91:1<32::AID-IJC1004>3.0.CO;2-J     Document Type: Article

References (54)

1. Toxicity and partial structure of a hepatotoxic peptide produced by the cyanobacterium Nodularia spumigena Mertens emend. L575 from New Zealand
2. Identification of protein phosphatase inhibitors of the microcystin class in the marine environment
3. Death of a dog attributed to the cyanobacterial (blue-green algae) hepatotoxin nodularin in South Africa
4. Tumor promotion and TNF-α gene expression by the okadaic acid class tumor promoters
5. Cyanobacterial nodularin is a potent inhibitor of type 1 and type 2A protein phosphatases
6. Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases
7. Expression of the tumor necrosis factor a gene and early response genes by nodularin, a liver tumor promoter in primary cultured rat hepatocytes
8. Nodularin, a potent inhibitor of protein phosphatases 1 and 2A, is a new environmental carcinogen in male F344 rat liver
9. Effect of nodularin on the expression of glutathione-S-transferase placental form and proliferating cell nuclear antigen in N-nitrosodiethylamine initiated hepatocarcinogenesis in the male Fischer 344 rat
10. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat
11. Morphometric analysis of the ultrastructural changes in rat liver induced by the peroxisome proliferator SaH 42-348
12. The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes
13. Peroxisome proliferator nafenopin potentiated cytotoxicity and genotoxicity of cyclophosphamide in the liver and bone marrow cells
14. Induction of peroxisomal acyl CoA oxidase activity and lipid peroxidation in primary rat hepatocyte cultures
15. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexy-1)phthalate and [4-chloro-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats
16. Evaluation of liver cell proliferation during ciprofibrate-induced hepatocarcinogenesis
17. Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver loci occurring spontaneously
18. Differences between the promoting activities of the peroxisome proliferator Wy-14,643 and phenobarbital in rat liver
19. A fatty acyl-CoA oxidizing system in rat liver peroxisomes: Enhancement by clofibrate, a hypolipidemic drug
20. Sequential histologic study of rat liver during peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]-acetic acid (Wy-14,643)-induced carcinogenesis
21. A species comparison of acute H hyperplasia induced by the peroxisome proliferator methylclofenapate: Involvement of the binucleated hepatocyte
22. An in vitro model of rodent nongenotoxic hepatocarcinogenesis
23. Induction of peroxisomal beta-oxidation and P-450 4A-dependent activities by pivalic and trichloroacetic acid in rat liver and kidney
24. A comparative study of the anatomy of rat and human livers
25. Protein (serine and threonine) phosphate phosphatases
26. Protein phosphatase-1 and protein phosphatase-2A from rabbit skeletal muscle
27. A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase
28. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis
29. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens
30. Carcinogenicity of peroxisome proliferators. Evaluation and mechanisms
31. Use of primary cultures of adult rat hepatocytes to investigate mechanisms of action of nafenopin, a hepatocarcinogenic peroxisome proliferator
32. Peroxisome proliferation and non-genotoxic carcinogenesis: Commentary on a symposium
33. Lack of DNA damage or lipid peroxidation measured in vivo in the rat liver following treatment with peroxisomal proliferators
34. The peroxisome proliferator class of nongenotoxic hepatocarcinogens synergize with epidermal growth factor to promote clonal expansion of initiated rat hepatocytes
35. Ciprofibrate, a carcinogenic peroxisome proliferator, increases the phosphorylation of the epidermal growth factor receptor
36. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters
37. Apoptosis: Regulation and relevance to toxicology
38. Induction of acyl-CoA oxidase and cytochrome P450IVA1 RNA in rat primary hepatocyte culture by peroxisome proliferators
39. Microsomal lauric acid hydroxylase activities after treatment of rats with three classical cytochrome P450 inducers and peroxisome proliferating compounds
40. Co-induction of cytochrome P4504A1 and peroxisome proliferation: A causal or casual relationship?
41. The cytochrome P450 4 (CYP4) family
42. Comparison of dose-response relationships for induction of lipid metabolizing and growth regulatory genes by peroxisome proliferators in rat liver
43. Differential effects of ciprofibrate on renal and hepatic cytochrome P450 2E1 expression
44. The different susceptibility of rat liver lobes to carbon tetrachloride and dimethylnitrosamine
45. Carbon tetrachloride-induced hepatotoxicity in rats: Evidence for different susceptibilities of rat liver lobes
46. Biochemical and morphologic studies of heterogeneous lobe responses in hepatocarcinogenesis
47. 4-alkylthymidine following exposure to methylating and ethylating hepatocarcinogens
48. Non-genotoxic hepatocarcinogenesis in vitro: The FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis
49. Inhibition of protein phosphatases by microcystins and nodularin associated with hepatotoxicity
50. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
51. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene
52. Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription
53. Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activator receptor alpha
54. Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis